The short answer
The bleeding risk of oral danshen root or rhizome with heparin remains uncertain. A recent study reported more bleeding with oral anticoagulants, but it explicitly excluded prior heparin prescribing and cannot supply a heparin risk estimate.
What this answer covers
Radix et Rhizoma Salviae Miltiorrhizae, confirmed Salvia miltiorrhiza root/rhizome oral product. Injectable danshen, isolated constituents and multi-herb formulas are distinct.
- Supplement or preparation
- Radix et Rhizoma Salviae Miltiorrhizae
- Medication ingredient
- heparin
An oral-anticoagulant study raises concern
A self-controlled study found more bleeding during early periods of co-prescribed Salvia miltiorrhiza and oral anticoagulants. Patients served as their own comparison over time, but dispensing records did not prove ingestion and changing illness or treatment could still influence the findings.
It did not answer the heparin question
The study covered warfarin and direct oral anticoagulants and excluded patients with heparin prescribing before the index date. Its risk estimates should therefore not be described as heparin findings. The anticoagulant mechanisms and clinical settings differ.
Root products and injections are not equivalent
The exposure included single-herb and combination prescriptions, not a standardized trial of this exact root/rhizome product. A report about injected danshen would also have a different route. These boundaries leave uncertainty about the product and regimen relevant to an individual patient.
A cautious review remains appropriate
Tell the heparin team about the exact supplement before starting or changing it. Report unusual bleeding or bruising promptly; serious bleeding, black stools or vomiting blood needs urgent assessment. Do not change prescribed heparin yourself. No heparin dose change or protective dosing interval can be derived from the oral-anticoagulant study.
Evidence and practical considerations
Side effects & toxicity
Current oral-anticoagulant bleeding study excluded prior heparin and used variable prescriptions. It supports concern for review but cannot establish an exact oral-root/heparin bleeding interaction.
- Exact scope
- Radix et Rhizoma Salviae Miltiorrhizae, confirmed Salvia miltiorrhiza root/rhizome oral product. Injectable danshen, isolated constituents and multi-herb formulas are distinct. with Unfractionated heparin sodium intravenous/subcutaneous, active-ingredient bridge to RxCUI5224 IN. Not LMWH or topical therapy.
- Medication form and route
- intravenous or subcutaneous unfractionated heparin; oral supplement
What remains uncertain
- No universal risk estimate, dose adjustment or spacing interval; source-specific limits apply.
Factors that may matter: Exact product; Dose/duration; Other antithrombotics; Bleeding risk; Kidney function.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People receiving parenteral unfractionated heparin.
Heparin can cause hemorrhage; medicines inhibiting platelets can add bleeding concerns. Aldosterone suppression can cause hyperkalemia, especially with predisposing conditions or potassium-sparing medicines. Heparin is not absorbed through the gastrointestinal tract.
How this applies: Exact species, preparation, route and measured endpoints govern applicability; other anticoagulants are not silently treated as heparin.
No botanical interaction specifically named. Not low-molecular-weight heparin, topical heparin cream or an oral anticoagulant; doses and risks of catheter flush products are not automatically equivalent.
Source 2: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 525co-prescribed patients;146with bleeding events included in self-controlled analysis.
Bleeding incidence was higher during early concomitant dispensing periods with oral anticoagulants than during comparison periods.
How this applies: Exact species, preparation, route and measured endpoints govern applicability; other anticoagulants are not silently treated as heparin.
Prior heparin prescribing was excluded. Observational dispensing records, possible residual/time-varying confounding, mixed formulas; no exact root/rhizome powder or heparin risk estimate.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared exact-pair article preserving route, formulation, clinical-outcome and laboratory-endpoint distinctions. | |
| Research summary published |
Article revision: 611bc5c48cf70418
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.